Daily Brief Health Care: scPharmaceuticals Inc, Cooper Cos, Pro Medicus Ltd, Veeva Systems Inc Class A, D.Western Therapeutics Institute Inc., Apollo Hospitals Enterprise, Agilent Technologies and more

• TaskUs privatization bid at $16.50/share faces opposition; market anticipates improved offer before September 10 shareholder vote.
• Apiam Animal Health receives A$0.88/share takeover offer; largest shareholder supports, board likely to recommend upon binding agreement.
• Banxa shareholders approve OSL Group acquisition; regulatory consents pending, closing expected Q4’25–Q1’26, spread at 21%.

• Cooper Companies recently reported its third-quarter financial results for the fiscal year 2025, showcasing a mixed performance.
• Consolidated revenues increased by 5.7% year-over-year, reaching $1.06 billion, although organic growth was slightly muted at 2%.
• Margins improved, contributing to a non-GAAP earnings growth of 15% to $1.10 per share.

Key points (machine generated)

• Pro Medicus is known for its Visage PACS software, which outperforms legacy systems from major OEMs.
• The company’s market potential is limited due to annual contract values of $1-4 million and financial pressures on hospitals.
• Strong competitors like Sectra and potential enhancements from Epic pose threats to Pro Medicus’s market position.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

• Veeva Systems recently concluded a noteworthy second quarter for fiscal 2026, reporting total revenue of $789 million and non-GAAP operating income reaching $353 million, reflecting the company’s strong performance and execution.
• Both analyst queries and management responses highlighted several key developments impacting Veeva’s strategic trajectory, providing insights into the opportunities and challenges facing the company.
• Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

• SIR believes DWTI has entered an exciting new phase given significant advances in pipeline development achieved over the last year.
• Key advances included: 1) publishing favorable topline results of in-house developed glaucoma treatment [H- 1337] Phase IIb US trials (strong prospects as “first choice as a second-line drug”),
• 2) commenced joint development Japan Phase II clinical trials of regenerative cell therapy [DWR-2206] with ActualEyes, and successfully completed all transplants…

• Apollo Hospitals Enterprise (APHS IN) delivered robust performance in Q1FY26, with double-digit revenue growth across all three business verticals and continuous margin expansion.
• Hospital business revenue grew 11% YoY to INR29B, driven by inpatient volume (+3%) and favorable price and case mix (+8%). Margin improvement continued, with EBITDA margin expanding 88bps to 24.5%.
• Apollo anticipates continued double digit revenue growth for FY26, underpinned by strong performance of the existing hospitals and new hospital openings.

• Agilent Technologies, Inc.’s third quarter 2025 earnings present a picture of a company experiencing robust revenue performance even as it navigates a complex global market environment.
• Agilent reported revenues of $1.74 billion for the quarter, surpassing its guidance and reflecting a core revenue growth of 6.1%.
• The earnings per share were $1.37, which was within expected ranges, showing a growth of 4% year over year.